Generic Name and Formulations:
Captopril, hydrochlorothiazide; 25mg/15mg, 25mg/25mg, 50mg/15mg, 50mg/25mg; scored tabs.
Various generic manufacturers
- Angiotensin System Inhibitors Improve OS in mRCC
- Photosensitizing Antihypertensive Agents Linked to Lip Cancer in Non-Hispanic Whites
- Angiotensin-Converting Enzyme (ACE) Inhibitors for Hypertension
- Combination Treatments for Hypertension Chart
- Diuretics for Hypertension
Indications for Captopril/Hydrochlorothiazide:
Take 1 hr before meals. As initial therapy: one 25/15 tab daily; adjust at 6 wk intervals. Previously titrated: use same doses as individual components. Usual max 150mg captopril, 50mg hydrochlorothiazide daily.
See full labeling.
Anuria. Sulfonamide allergy. History of ACEI-associated angioedema.
Fetal toxicity may develop: discontinue if pregnancy is detected. Renal or hepatic dysfunction. Salt/volume depletion. CHF. Dialysis (esp. high-flux membrane). Aortic stenosis. Diabetes. Gout. Asthma. Postsympathectomy. Surgery. Monitor electrolytes. Monitor WBCs and renal function in renal and collagen vascular disease. Discontinue if neutropenia, agranulocytosis, angioedema or laryngeal edema occurs. Pregnancy (Cat.D in 2nd and 3rd trimesters). Nursing mothers: not recommended.
ACE inhibitor + diuretic.
Potentiated by antihypertensives. Potentiates tubocurarine. May antagonize sulfonylureas, oral anticoagulants, uricosurics. May be antagonized by NSAIDs, sympathomimetics. May increase digitalis, lithium, insulin, diazoxide toxicity. Hyperkalemia with potassium-sparing diuretics and supplements. Hypokalemia with ACTH, corticosteroids. Orthostatic hypotension may be increased by alcohol, CNS depressants. May interfere with parathyroid, urinary acetone tests.
Neutropenia, agranulocytosis, proteinuria, nephrotic syndrome, orthostatic hypotension, fluid or electrolyte imbalance, rash, GI upset, dysgeusia, hyperglycemia, hyperuricemia, dizziness, headache, cough, pruritus, angioedema, tachycardia, chest pain, jaundice, blurred vision.
Formerly known under the brand name Capozide.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Predicting Response to Immunotherapy in Late-Stage Melanoma
- Genetic Counseling Recommended for Advanced Prostate Cancer
- A Simplified Dose Schedule of Cetuximab as a Maintenance Therapy in Head and Neck Cancer May Reduce Drug Toxicities
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Transplant Status May Affect CAR-T Therapy Outcomes in CLL and B-ALL
- Study Zeroes in on Cause of Castration-Resistant Prostate Cancer
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline